Ultra-Long Acting Insulin Glargine

超长效甘精胰岛素

• 批准号: 710797
• 金额: $ 7.6万
• 依托单位: ARECOR LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710797
• 关键词: Ultra; Long; Acting; Insulin; Glargine

The aim of the project is to use innovative formulation technology to develop a proof-ofconceptfor insulin product with a consistent, ultra-long release profile. Formulations will firstbe validated with the use of an in vitro model before demonstrating the ultra-long releaseprofile in a relevant animal model. Arecor is a biotherapeutic formulation company with atechnology that has the ability to elongate the time action profile of insulin whilst maintaininga product stability profile suitable for commercialisation. The duration of action for currentlymarketed products is less than 24 hours in at least a third of patients, which increases the riskof severe life-threatening hypoglycaemic episodes. A consistent, elongated release profile willoffer reduced hypoglycaemic risk, whilst in turn improving dose flexibility resulting inimproved patient compliance, health benefits and savings for the healthcare provider.

该项目的目的是使用创新的配方技术开发具有一致的超长释放曲线的胰岛素产品的概念验证。在相关动物模型中证明超长释放曲线之前，将首先使用体外模型对制剂进行验证。Arecor是一家生物制剂公司，其技术能够延长胰岛素的时间作用曲线，同时保持适合商业化的产品稳定性。目前市售产品的作用持续时间在至少三分之一的患者中少于24小时，这增加了严重危及生命的低血糖发作的风险。持续、延长的释放曲线将降低低血糖风险，同时反过来提高剂量灵活性，从而提高患者依从性，为医疗保健提供者带来健康益处和节省。